The activation of LKB1/AMPK inhibits the migration of TGF-β–stimulated cancer cells by inhibiting Smad2/3 activity, which suggests that AMPK may be a target for cancer drug therapy [42]. The gene discussed is SMAD2; the disease is cancer.